MN-166 Sales Forecast, and Market Size Analysis – 2034

Key Factors Driving MN-166 Growth

1. Advancement Through Pivotal Clinical Trials in ALS

• MediciNova recently completed enrollment in the COMBAT-ALS Phase II/III randomized, placebo-controlled trial evaluating MN-166 in amyotrophic lateral sclerosis (ALS), with 234 patients enrolled across the US and Canada.
• This trial is designed to assess efficacy, safety, and functional impact over 12 months, with top-line results expected by the end of 2026.
• MN-166 has also received Orphan Drug Designations and Fast Track status from the US FDA, which may expedite review and provide incentives like extended market exclusivity if approved.

2. Prior Clinical Evidence Suggesting Effect in Progressive MS and Neuroprotection

• In earlier Phase IIb studies (e.g., SPRINT-MS), MN-166 was associated with a 26% reduction in confirmed disability progression and slowed brain atrophy in progressive multiple sclerosis (MS).
• Ibudilast’s mechanism — inhibiting pro-inflammatory cytokines and promoting neurotrophic factors — supports its role in slowing disease processes in chronic neurological disorders.

3. Multi-Indication Development Strategy

MediciNova is positioning MN-166 in a diverse series of indications, each representing a meaningful unmet medical need:

• Degenerative cervical myelopathy (DCM): Phase III development design or progression.
• Long COVID and substance use disorders: Ongoing Phase II explorations.
• Chemotherapy-induced peripheral neuropathy (CIPN): Phase II OXTOX trial nearing completion, with results expected in 2026.

This multi-indication strategy spreads development risk and enhances long-term growth potential if MN-166 demonstrates meaningful clinical benefit across several conditions.

4. Regulatory Support and Incentives

MN-166 has received regulatory designations that provide commercial and development advantages:

• Orphan Drug Designation from the US FDA and EMA (in ALS, and potentially other indications).
• Fast Track Designation from the US FDA, which could accelerate clinical interactions and review timelines.

5. Strengthening Intellectual Property and Formulation Expansion

• MediciNova has secured patents for extended-release formulations of MN-166, extending potential market exclusivity through at least 2040 in the US and enhancing product differentiation (e.g., improved adherence and convenience).
• Additional formulation development — such as parenteral options — may broaden clinical utility for certain indications.

MN-166 Recent Developments

• In January 2026, MediciNova, a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS; NCT 06743776) representing 50% of the planned 200-enrollment, evaluating MN‑166 (Ibudilast) in patients with amyotrophic lateral sclerosis (ALS).
• In December 2025, MediciNova, a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS), known as the COMBAT-ALS study. These results were presented at the 36th International Symposium on ALS/MND.

“MN-166 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of MN-166 for approved indication like Allergic conjunctivitis, Asthma, and Cerebrovascular disorders; as well as potential indications like Spinal cord disorders, Amyotrophic lateral sclerosis, Post acute COVID 19 syndrome, Alcoholism, Multiple sclerosis, and Opioid-related disorders in the 7MM. A detailed picture of MN-166’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the MN-166 for approved and potential indications. The MN-166 market report provides insights about MN-166’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current MN-166 performance, future market assessments inclusive of the MN-166 market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of MN-166 sales forecasts, along with factors driving its market.

MN-166 Drug Summary

MN-166 (Ibudilast) is an orally bioavailable, first-in-class small-molecule glial attenuator developed by MediciNova that selectively inhibits phosphodiesterases (PDE3, PDE4, PDE10, PDE11) and macrophage migration inhibitory factor (MIF), while acting as a toll-like receptor 4 (TLR4) antagonist to suppress pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6), attenuate microglial activation/neuroinflammation, and promote neuroprotective effects including nerve growth factor upregulation and reduced oxidative stress. Originally approved in Japan over 20 years ago as an asthma bronchodilator (10-40 mg/day), it is repurposed at higher doses (50-100 mg/day) for neurodegenerative disorders, demonstrating in Phase II ALS trials (NCT02238626, COMBAT-ALS) a favorable safety profile, higher treatment responder rates (21% vs. 12% placebo on ALSFRS-R), and trends toward slower progression; in progressive MS (Phase II ARISE trial), it reduced brain atrophy, persistent black holes, and disability progression risk by ~50%; with ongoing Phase IIb/III COMBAT-ALS enrollment completed in 2025, FDA Fast Track/Orphan Drug status for ALS, and exploration in glioblastoma, CIPN, substance use disorder, and Long COVID. Common adverse events are dose-dependent nausea, diarrhea, headache, and elevated liver enzymes, generally mild and transient. The report provides MN-166’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the MN-166 Market Report

The report provides insights into:

• A comprehensive product overview including the MN-166 MoA, description, dosage and administration, research and development activities in approved indications like Allergic conjunctivitis, Asthma, and Cerebrovascular disorders; as well as potential indications like Spinal cord disorders, Amyotrophic lateral sclerosis, Post acute COVID 19 syndrome, Alcoholism, Multiple sclerosis, and Opioid-related disorders.
• Elaborated details on MN-166 regulatory milestones and other development activities have been provided in MN-166 market report.
• The report also highlights MN-166‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The MN-166 market report also covers the patents information, generic entry and impact on cost cut.
• The MN-166 market report contains current and forecasted MN-166 sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The MN-166 market report also features the SWOT analysis with analyst views for MN-166 in approved and potential indications.

Methodology

The MN-166 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MN-166 Analytical Perspective by DelveInsight

• In-depth MN-166 Market Assessment

This MN-166 sales market forecast report provides a detailed market assessment of MN-166 for approved indication like Allergic conjunctivitis, Asthma, and Cerebrovascular disorders; as well as potential indications like Spinal cord disorders, Amyotrophic lateral sclerosis, Post acute COVID 19 syndrome, Alcoholism, Multiple sclerosis, and Opioid-related disorders in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted MN-166 sales data uptil 2034.

• MN-166 Clinical Assessment

The MN-166 market report provides the clinical trials information of MN-166 for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

MN-166 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

MN-166 Market Potential & Revenue Forecast

• Projected market size for the MN-166 and its key indications
• Estimated MN-166 sales potential (MN-166 peak sales forecasts)
• MN-166 Pricing strategies and reimbursement landscape

MN-166 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• MN-166 Market positioning compared to existing treatments
• MN-166 Strengths & weaknesses relative to competitors

MN-166 Regulatory & Commercial Milestones

• MN-166 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

MN-166 Clinical Differentiation

• MN-166 Efficacy & safety advantages over existing drugs
• MN-166 Unique selling points

MN-166 Market Report Highlights

• In the coming years, the MN-166 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The MN-166 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MN-166’s dominance.
• Other emerging products for Allergic conjunctivitis, Asthma, and Cerebrovascular disorders; as well as potential indications like Spinal cord disorders, Amyotrophic lateral sclerosis, Post acute COVID 19 syndrome, Alcoholism, Multiple sclerosis, and Opioid-related disorders are expected to give tough market competition to MN-166 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MN-166 in approved and potential indications.
• Analyse MN-166 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted MN-166 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of MN-166 in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of MN-166? How strong is MN-166’s clinical and commercial performance?
• What is MN-166’s clinical trial status in each individual indications such as Allergic conjunctivitis, Asthma, and Cerebrovascular disorders; as well as potential indications like Spinal cord disorders, Amyotrophic lateral sclerosis, Post acute COVID 19 syndrome, Alcoholism, Multiple sclerosis, and Opioid-related disorders and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MN-166 Manufacturers?
• What are the key designations that have been granted to MN-166 for approved and potential indications? How are they going to impact MN-166’s penetration in various geographies?
• What is the current and forecasted MN-166 market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of MN-166 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to MN-166 for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is MN-166? What is the duration of therapy and what are the geographical variations in cost per patient?

Show more